A detailed history of Susquehanna International Group, LLP transactions in Keros Therapeutics, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 15,425 shares of KROS stock, worth $704,922. This represents 0.0% of its overall portfolio holdings.

Number of Shares
15,425
Previous 15,532 0.69%
Holding current value
$704,922
Previous $617,000 65.48%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 07, 2024

SELL
$41.26 - $70.48 $4,414 - $7,541
-107 Reduced 0.69%
15,425 $1.02 Million
Q4 2023

Feb 14, 2024

BUY
$27.12 - $41.05 $421,227 - $637,588
15,532 New
15,532 $617,000
Q2 2023

Aug 11, 2023

SELL
$37.26 - $51.01 $662,594 - $907,110
-17,783 Reduced 66.97%
8,770 $352,000
Q1 2023

May 16, 2023

BUY
$41.44 - $59.32 $768,546 - $1.1 Million
18,546 Added 231.62%
26,553 $1.13 Million
Q4 2022

Feb 14, 2023

SELL
$39.45 - $51.77 $1.11 Million - $1.45 Million
-28,015 Reduced 77.77%
8,007 $384,000
Q3 2022

Nov 14, 2022

BUY
$27.8 - $40.12 $1 Million - $1.45 Million
36,022 New
36,022 $1.36 Million
Q2 2022

Aug 15, 2022

SELL
$26.03 - $67.04 $521,771 - $1.34 Million
-20,045 Closed
0 $0
Q1 2022

May 16, 2022

BUY
$42.12 - $59.36 $114,229 - $160,984
2,712 Added 15.65%
20,045 $1.09 Million
Q4 2021

Feb 14, 2022

BUY
$36.95 - $62.89 $161,841 - $275,458
4,380 Added 33.81%
17,333 $1.01 Million
Q3 2021

Nov 15, 2021

BUY
$29.27 - $43.71 $123,812 - $184,893
4,230 Added 48.49%
12,953 $512,000
Q2 2021

Aug 11, 2021

BUY
$42.4 - $70.11 $369,855 - $611,569
8,723 New
8,723 $370,000
Q1 2021

May 17, 2021

SELL
$54.0 - $75.28 $345,492 - $481,641
-6,398 Closed
0 $0
Q4 2020

Feb 16, 2021

BUY
$36.0 - $82.74 $230,328 - $529,370
6,398 New
6,398 $451,000

Others Institutions Holding KROS

About Keros Therapeutics, Inc.


  • Ticker KROS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 25,757,000
  • Market Cap $1.18B
  • Description
  • Keros Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel treatments for patients suffering from hematological and musculoskeletal disorders with high unmet medical need. The company's lead protein therapeutic product candidate is KER-050, which is being developed ...
More about KROS
Track This Portfolio

Track Susquehanna International Group, LLP Portfolio

Follow Susquehanna International Group, LLP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

News

Stay updated on Susquehanna International Group, LLP with notifications on news.